Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

Shares of Amgen (AMGN) were in the spotlight on Monday morning after the company announced that its immunotherapy Imdelltra ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

RALEIGH, N.C., May 13, 2025 /PRNewswire/ -- Lung cancer patients from across the country gathered recently in Raleigh, NC, for the nation's only summit created exclusively for Small Cell Lung ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas. The first patient was dosed in the SKYBRIDGE ...

May 14 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV.N), opens new tab drug to treat adults with a type of lung cancer who have received previous treatment, the ...

1 inhibitor approved for both perioperative and neoadjuvant-only treatment of resectable non-small cell lung cancer in the European Union ...